Substance / Medication

Fluvoxamine

Overview

Active Ingredient
fluvoxamine
RxNorm CUI
42355

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

7 trials linked to this intervention

7
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Evaluating fluvoxamine for the outpatient treatment of COVID-19: A systematic review and meta-analysis.
Deng Jiawen, Moskalyk Myron, Zuo Qi Kang et al. · Rev Med Virol · 2024
PMID: 38148036Meta-Analysis
Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials.
Vatvani Akhil Deepak, Kurniawan Andree, Hariyanto Timotius Ivan · Ann Pharmacother · 2023
PMID: 37002592Meta-AnalysisFull text (PMC)
Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
Yu Chia-Ling, Carvalho Andre F, Thompson Trevor et al. · Int J Environ Res Public Health · 2023
PMID: 36901099Meta-AnalysisFull text (PMC)
A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference.
Marcec Robert, Dodig Vinko Michael, Likic Robert · J Infect · 2023
PMID: 36403698Meta-AnalysisFull text (PMC)
Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis.
Lee Todd C, Vigod Simone, Bortolussi-Courval Émilie et al. · JAMA Netw Open · 2022
PMID: 35385087Meta-AnalysisFull text (PMC)
Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis.
Lu Li-Chin, Chao Chien-Ming, Chang Shen-Peng et al. · J Infect Public Health · 2022
PMID: 36272390Meta-AnalysisFull text (PMC)
Fluvoxamine for the treatment of COVID-19.
Nyirenda John Lz, Sofroniou Mario, Toews Ingrid et al. · Cochrane Database Syst Rev · 2022
PMID: 36103313Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fluvoxamine (substance)
SNOMED CT
372905008
UMLS CUI
C0085228
RxNorm CUI
42355

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

3
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Fluvoxamine — Conditions, Biomarkers & Specialists | Healos | Ltrl